Get startedLog in
    Picture of Hamlet BioPharma AB logo

    HAMLET B — Hamlet BioPharma AB Income Statement

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapMomentum Trap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Hamlet BioPharma AB, fiscal year end - June 30th, SEK millions except per share, conversion factor applied.

    2020
    June 30th
    2021
    June 30th
    2022
    June 30th
    2023
    June 30th
    2024
    June 30th
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSPRESS
    Standards:
    SAS
    SAS
    SAS
    SAS    		—
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue00000
    Cost of Revenue
    Gross Profit———-15.9-25.2
    Selling / General / Administrative Expenses
    Depreciation and Amortization
    Other Operating Expenses
    Total Operating Expenses23.47.517.120.542.5
    Operating Profit-23.4-7.5-17.1-20.5-42.5
    Total Net Non Operating Interest Income / Expense
    Net Income Before Taxes-23.4-7.72-17.2-20.4-41.8
    Provision for Income Taxes
    Net Income After Taxes-23.4-7.72-17.2-20.4-41.8
    Net Income Before Extraordinary Items
    Net Income-23.4-7.72-17.2-20.4-41.8
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income-23.4-7.72-17.2-20.4-41.8
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS-0.22-0.073-0.15-0.176-0.249
    Dividends per Share